Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glauco Radoslovich

Clinical Cardiac Electrophysiology Hackensack, NJ Medical Doctor

NPI 1598732935 CMS profile 299452

20 Prospect Ave, Ste 701, Hackensack, NJ 07601

Open in the dashboard

General payments

$14,965

410 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glauco Radoslovich of Hackensack, NJ is reported in the CMS Open Payments database as having received $14,965 across 410 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,661 46
2024 General $3,586 58
2023 General $3,146 75
2022 General $1,463 61
2021 General $1,195 37
2020 General $943 45
2019 General $1,971 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glauco Radoslovich
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Glauco Radoslovich were reported at $2,661. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Glauco Radoslovich Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,971 $2,361 $585–$8,260 $163
2020 $943 $993 $247–$4,351 $114
2021 $1,195 $1,185 $326–$4,739 $132
2022 $1,463 $2,073 $554–$6,789 $149
2023 $3,146 $2,568 $759–$8,159 $160
2024 $3,586 $2,557 $703–$7,403 $164
2025 $2,661 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $5,906 155 payments
  2. Medtronic, Inc. $4,758 126 payments
  3. Abbott Laboratories $1,780 28 payments
  4. Medtronic Vascular, Inc. $460 25 payments
  5. E.R. Squibb & Sons, L.L.C. $300 13 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $277 14 payments
  7. Sanofi-Aventis U.S. LLC $211 8 payments
  8. Atricure, Inc. $191 5 payments
  9. CVRx, Inc. $184 2 payments
  10. Biotronik Inc. $180 9 payments
  11. Other $720 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,265 387 payments
  2. Travel and Lodging $2,630 22 payments
  3. Education $70 1 payment
Products named General payments · program years 2019–2025
  1. Micra $1,155 44 payments
  2. INGEVITY+ $1,033 14 payments
  3. AVEIR Structural Heart $800 9 payments
  4. RESONATE EL ICD VR $759 8 payments
  5. EMBLEM MRI S-ICD $584 12 payments
  6. AVEIR Structural Heart $520 9 payments
  7. RESONATE $467 15 payments
  8. General - Therapies $430 14 payments
  9. SelectSecure $402 31 payments
  10. COBALT DR MRI SURESCAN $294 5 payments
  11. Other $5,679 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

631

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$320,898

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

46.8%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 138 $184,169
Xarelto Rivaroxaban Brand 59 $80,318
Multaq Dronedarone Hcl Brand 25 $36,816
Pradaxa Dabigatran Etexilate Mesylate Brand 17 $5,129
Metoprolol Succinate Generic 175 $3,877
Propafenone Hcl Er Propafenone Hcl Brand 20 $2,985
Mexiletine Hcl Generic 11 $2,027
Amiodarone Hcl Generic 60 $1,943
Sotalol Sotalol Hcl Brand 21 $963
Flecainide Acetate Generic 19 $946

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$226,721

Medicare's payments for the services billed

Medicare patients

1,450

Average age 79

Services billed

4,300

712 women, 738 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 54%
Atrial fibrillation 53%
Heart failure 51%
Diabetes 46%
Chronic kidney disease 38%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $122
$122 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $11
$11 138 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

410 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record